2.035

3.55% -0.075

After Hours: 2.08 0.045 +2.21%

Inovio Pharmaceuticals Inc (INO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Inovio Pharmaceuticals Inc stock is traded at $2.035, with a volume of 903.37K. It is down -3.55% in the last 24 hours and up +1.75% over the past month. Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Previous Close:

$2.11

Open:

$2.15

24h Volume:

903.37K

Relative Volume:

1.39

Market Cap:

$82.52M

Revenue:

$832.00K

Net Income/Loss:

$-135.12M

P/E Ratio:

-0.3342

EPS:

-6.09

Net Cash Flow:

$-124.69M

1W Performance:

+5.44%

1M Performance:

+1.75%

6M Performance:

+14.33%

1Y Performance:

-74.81%

1-Day Range:

$2.02

$2.18

1-Week Range:

$1.955

$2.2989

52-Week Range:

$1.42

$12.33

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Name

Inovio Pharmaceuticals Inc

Sector

Healthcare (1173)

Industry

Biotechnology (661)

Phone

(858) 410-3134

Address

660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA

Employee

134

Twitter

@inoviopharma

Next Earnings Date

2024-11-07

Latest SEC Filings

INO's Discussions on Twitter

Compare INO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INO Inovio Pharmaceuticals Inc	2.035	82.52M	832.00K	-135.12M	-124.69M	-6.09
VRTX Vertex Pharmaceuticals Inc	445.20	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	525.00	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	326.09	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	551.22	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	242.07	28.51B	3.81B	-644.79M	-669.77M	-6.24

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-14-24	Initiated	Stephens	Overweight
Jan-25-24	Upgrade	Oppenheimer	Perform → Outperform
Nov-09-22	Downgrade	Maxim Group	Buy → Hold
Nov-01-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-19-22	Resumed	RBC Capital Mkts	Sector Perform
May-11-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-21-22	Upgrade	BofA Securities	Underperform → Neutral
Dec-29-21	Resumed	Jefferies	Hold
Sep-10-21	Downgrade	BofA Securities	Neutral → Underperform
Jun-24-21	Initiated	Jefferies	Hold
Mar-23-21	Initiated	BofA Securities	Neutral
Feb-12-21	Initiated	Oppenheimer	Outperform
Nov-17-20	Downgrade	ROTH Capital	Neutral → Sell
Nov-10-20	Upgrade	ROTH Capital	Sell → Neutral
Sep-28-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-28-20	Upgrade	Maxim Group	Hold → Buy
Jul-01-20	Downgrade	Maxim Group	Buy → Hold
Jul-01-20	Downgrade	ROTH Capital	Neutral → Sell
Jun-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-26-20	Downgrade	Stifel	Buy → Hold
May-21-20	Initiated	The Benchmark Company	Buy
Apr-30-20	Downgrade	ROTH Capital	Buy → Neutral
Mar-13-20	Downgrade	Piper Sandler	Overweight → Neutral
Mar-13-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-19-19	Initiated	ROTH Capital	Buy
Feb-15-18	Reiterated	Maxim Group	Buy
Oct-18-17	Initiated	RBC Capital Mkts	Outperform
Sep-06-17	Initiated	Citigroup	Buy
Jun-08-17	Upgrade	Piper Jaffray	Neutral → Overweight
May-24-17	Reiterated	Maxim Group	Buy
Mar-16-17	Upgrade	Maxim Group	Hold → Buy
Mar-16-17	Downgrade	Piper Jaffray	Overweight → Neutral

View All

Inovio Pharmaceuticals Inc Stock (INO) Latest News

Jun 11, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript - MSN

Jun 11, 2025

Jun 09, 2025

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - AllSides

Jun 09, 2025

Human DNA Vaccines Market Set to Witness Breakthrough Advances - openPR.com

Jun 09, 2025

Jun 07, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Position Boosted by Bank of America Corp DE - Defense World

Jun 07, 2025

Jun 03, 2025

Deutsche Bank AG Has $164,000 Stock Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World

Jun 03, 2025

Jun 01, 2025

Northern Trust Corp Grows Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World

Jun 01, 2025

May 30, 2025

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

May 30, 2025

May 27, 2025

Inovio’s SWOT analysis: dna immunotherapy firm faces crucial year for stock - Investing.com Australia

May 27, 2025

May 23, 2025

Inovio shareholders approve board nominees and proposals By Investing.com - Investing.com Canada

May 23, 2025

May 22, 2025

Inovio shareholders approve board nominees and proposals - Investing.com Australia

May 22, 2025

Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline - MSN

May 15, 2025

May 14, 2025

Inovio Pharmaceuticals (INO) Maintains Sector Perform Rating by RBC Capital | INO Stock News - GuruFocus

May 14, 2025

Oppenheimer cuts Inovio stock price target to $13 By Investing.com - Investing.com Nigeria

May 14, 2025

INO Reports Strong Q1 Revenue, Progress on INO-3107 Submission | - GuruFocus

May 14, 2025

Inovio (INO) Receives Revised Price Target from Oppenheimer | IN - GuruFocus

May 14, 2025

Inovio Pharmaceuticals: Hold Rating Due to Financial Losses and Uncertain Development Timeline - TipRanks

May 14, 2025

Inovio stock holds $12 target, JMP affirms Market Outperform By Investing.com - Investing.com Canada

May 14, 2025

Inovio stock holds $12 target, JMP affirms Market Outperform - Investing.com Australia

May 14, 2025